Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

cancer therapy

  • Home
  •  
  • cancer therapy



  • Most Read
  • Latest Comments
  • Noxopharm receives FDA approval for testing of promising cancer treatment
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Noxopharm receives FDA approval for testing of promising cancer treatment
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Noxopharm receives FDA approval for testing of promising cancer treatment
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Noxopharm receives FDA approval for testing of promising cancer treatment
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Noxopharm receives FDA approval for testing of promising cancer treatment
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Noxopharm’s pancreatic cancer treatment drug slows tumour growth in mice, study shows
    Noxopharm’s pancreatic cancer treatment drug slows tumour growth in mice, study shows
    • News

  • Noxopharm receives FDA designation for chemotherapy piggyback drug
    Noxopharm receives FDA designation for chemotherapy piggyback drug
    • News

  • Q&A: Paradigm to answer FDA questions to achieve Investigational New Drug status
    Q&A: Paradigm to answer FDA questions to achieve Investigational New Drug status
    • News

  • Noxopharm receives FDA approval for testing of promising cancer treatment
    Noxopharm receives FDA approval for testing of promising cancer treatment
    • News

  • Noxopharm achieves significant pain relief for late-stage prostate cancer patients
    Noxopharm achieves significant pain relief for late-stage prostate cancer patients
    • News

  • Noxopharm receives FDA approval for testing of promising cancer treatment
    • News

    Noxopharm receives FDA approval for testing of promising cancer treatment

    Jennie Young was one of the first patients to receive Veyonda, Noxopharm’s (ASX: NOX) proprietary drug. Administered on compassionate grounds, her doctors believe that she responded to it positively. She had leiomyosarcoma, a rare cancer that affects smooth muscle tissue. Soft tissue sarcomas like hers have limited treatment options with only 14% responding to chemotherapy. 

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.